Hunan Provincial Respiratory Drug Engineering Technology Research Center
The Hunan Provincial Respiratory Drug Engineering Technology Research Center was established in 2013 with the approval of the Hunan Provincial Science and Technology Department, exclusively organized by Hunan Jiudian Pharmaceutical Co., Ltd. as the sole respiratory drug technology research and development platform in Hunan Province. The establishment of this center represents not only an enhancement of the company's own capabilities but also aligns with the national talent strategy. The center adopts a research and development model that prioritizes independent research and development, complemented by cooperative development and technology introduction. It focuses on consolidating existing competitive products within its specialized series while supplementing potential product lines and continuously developing new drugs based on market demands. Simultaneously, the company continuously optimizes the production processes of existing products, enabling rapid transformation of new products and technologies into productive forces to meet market needs. Its leading products, Levocetirizine Dihydrochloride Capsules and Tablets, are respectively the first domestically and the second nationally to pass the consistency evaluation. Additionally, the company has also applied for Ebastine Tablets under the new drug registration classification (deemed to have passed the consistency evaluation). The Engineering Technology Research Center will serve as a solid foundation for the transformation, complementation, and engineering of respiratory drug technology achievements in our province. It embodies the integration of industry, academia, and research, serving as an incubator for new respiratory drugs and gradually evolving into a technologically advanced and fully functional scientific research and development platform.
National Postdoctoral Research Workstation
Jiudian Pharmaceutical's Postdoctoral Research Workstation was established in 2018 as a national-level research platform approved by the Ministry of Human Resources and Social Security and the National Postdoctoral Management Committee. It aims to effectively build a bridge between enterprises and universities, serving as an important platform for enterprises to introduce and cultivate high-level talents. The company's postdoctoral research workstation has jointly cultivated postdoctoral fellows with multiple postdoctoral research stations, including the Postdoctoral Research Station of Central South University. Since its establishment, it has recruited and trained postdoctoral fellows at a growth rate of over 30%, with a total of 4 doctoral students recruited, among which 3 have successfully completed their studies, 1 is currently in the station, and 2 are planned to enter the station. The company's postdoctoral research workstation undertakes forward-looking research projects and related industrial expansion research, becoming an important scientific research institution for the enterprise. Its research directions cover innovative drugs, improved new drug research and development, process optimization, sustained-release and controlled-release formulations, and other high-end formulations, as well as clinical fields, providing strong support for the enterprise's industrial development and production operations.
Hunan Provincial Engineering Technology Research Center for Molecular Characteristics of Inorganic Salt Raw Materials and Adjuvants
The Hunan Provincial Engineering Technology Research Center for Molecular Characteristics of Inorganic Salt Raw Materials and Adjuvants was established in 2023 with the approval of the Hunan Provincial Science and Technology Department. Jiudian Hongyang, as the leading force behind this center, has conducted extensive research on inorganic salt raw materials and adjuvants, developing multiple core and key technologies, and has secured a prominent market share in this field. Notably, its phosphate series products account for 60% of the national market, making it the exclusive supplier to some of China's essential vaccine manufacturers. Leveraging Jiudian Hongyang's strengths in talent, technology, and R&D equipment, the Hunan Provincial Engineering Technology Research Center for Molecular Characteristics of Inorganic Salt Raw Materials and Adjuvants delves deeply into the molecular characteristics of these materials. By conducting in-depth exploration, product development, and quality standard formulation, the center significantly elevates the technological development level of inorganic salt raw materials and adjuvants in Hunan Province. This, in turn, propels the industrial development of medical-grade inorganic salt raw materials and adjuvants, fostering innovation and growth within the sector.
Hunan Engineering Research Center for Novel Gel Patches
The Hunan Engineering Research Center for Novel Gel Patches was officially approved and established by the Hunan Provincial Development and Reform Commission in 2013. It is an innovative platform relying on Hunan Jiudian Pharmaceutical Co., Ltd. as the main body, jointly established with Hunan University of Chinese Medicine and Hunan Pudao Pharmaceutical Technology Co., Ltd. The center focuses on the research of key common technologies, achievement transformation, and industrialization of transdermal patches, aiming to develop safe, efficient, and new transdermal patches with independent intellectual property rights, filling the gap in the research of transdermal patches in Hunan's pharmaceutical industry and significantly improving the technical development level of transdermal patches in the province. Loxoprofen Sodium Gel Patch is the first domestic generic and exclusive dosage form independently researched and developed by the engineering research and development center, drawing on advanced foreign gel patch preparation technology. After the drug was launched, it received unanimous recognition from patients and was affirmed by relevant experts, enjoying a good market background. Meanwhile, the center has also applied for Ketoprofen and Indomethacin Gel Patches (deemed to have passed the consistency evaluation) under the new drug registration classification. The products under research include three improved new drugs and the upgraded product of Loxoprofen Sodium Gel Patch, Loxoprofen Sodium Patch. The development of a series of competitive transdermal patches has significantly improved the competitiveness of Hunan's pharmaceutical enterprises in the domestic market, thereby promoting the rapid development of the transdermal patch industry in Hunan Province.
Hunan Provincial Engineering Technology Research Center for Molecular Characteristics of Inorganic Salt Raw Materials and Adjuvants
The Hunan Provincial Engineering Technology Research Center for Molecular Characteristics of Inorganic Salt Raw Materials and Adjuvants was established in 2023 with the approval of the Hunan Provincial Science and Technology Department. Jiudian Hongyang, as the leading force behind this center, has conducted extensive research on inorganic salt raw materials and adjuvants, developing multiple core and key technologies, and has secured a prominent market share in this field. Notably, its phosphate series products account for 60% of the national market, making it the exclusive supplier to some of China's essential vaccine manufacturers. Leveraging Jiudian Hongyang's strengths in talent, technology, and R&D equipment, the Hunan Provincial Engineering Technology Research Center for Molecular Characteristics of Inorganic Salt Raw Materials and Adjuvants delves deeply into the molecular characteristics of these materials. By conducting in-depth exploration, product development, and quality standard formulation, the center significantly elevates the technological development level of inorganic salt raw materials and adjuvants in Hunan Province. This, in turn, propels the industrial development of medical-grade inorganic salt raw materials and adjuvants, fostering innovation and growth within the sector.